Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GSK plc(GSK) Shareholders
Portfolio Pulse from
Levi & Korsinsky law firm has filed a securities class action lawsuit against GSK plc, alleging securities fraud between February 2020 and August 2022. The lawsuit claims GSK misled investors about the Zantac drug's potential cancer risks and the source of NDMA, suggesting the company knew about potential issues for nearly 40 years before withdrawing the drug from the market.
March 26, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The securities class action lawsuit alleges GSK misled investors about Zantac's safety and NDMA risks, which could result in potential financial damages and reputational harm.
The lawsuit directly targets GSK's statements about Zantac, potentially exposing the company to significant legal and financial risks. Allegations of securities fraud could negatively impact investor confidence and stock performance.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100